Parity as prognostic factor for malignant mixed müllerian tumours

Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1/ENGOT-ov25 trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2024

An uncommon case of POLE mutated uterine carcinosarcoma - complemented by a review of literature.

Gynecologic oncology reports·2024

ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease.

Annals of oncology : official journal of the European Society for Medical Oncology·2024

Combined chemotherapy and pembrolizumab salvages multi-chemotherapy agent and avelumab resistant choriocarcinoma: A case report.

Gynecologic oncology reports·2023

Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2023

Continuous versus intermittent extended adjuvant letrozole for breast cancer: final results of randomized phase III SOLE (Study of Letrozole Extension) and SOLE Estrogen Substudy.

Annals of oncology : official journal of the European Society for Medical Oncology·2021

Efficacy and safety of upadacitinib in adults and adolescents for treatment of non-segmental vitiligo (Viti-Up): results of two phase 3 randomised controlled studies.

Lancet (London, England)·2026

Belzutifan plus lenvatinib versus cabozantinib in patients with previously treated advanced renal cell carcinoma (LITESPARK-011): an open-label, randomised, controlled, phase 3 trial.

Lancet (London, England)·2026

Switch to once-weekly, single-tablet islatravir-lenacapavir from daily standard of care for HIV-1 (ISLEND-2): a multicentre, randomised, open-label, active-controlled, phase 3 non-inferiority trial.

Lancet (London, England)·2026

[177Lu]Lu-PSMA-617 in patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate cancer (PSMAddition): a phase 3 randomised, controlled trial.

Lancet (London, England)·2026

Mixed Reality-Based Versus Nurse Practitioner-Delivered Wound Care Education in the Emergency Department: A Prospective Randomized Study.

Journal of emergency nursing·2026

Early Hospital Practices Were Associated With Exclusive Breastfeeding Among Late Preterm and Early Term Infants.

Acta paediatrica (Oslo, Norway : 1992)·2026

Society for Maternal-Fetal Medicine Position Statement: Maternal mortality review committees.

Pregnancy (Hoboken, N.J.)·2026

Paired versus alternate breastfeeding: Does hindmilk become foremilk?

Pregnancy (Hoboken, N.J.)·2026

Abortion-related training in maternal-fetal medicine fellowship: A national survey of program directors and fellows.

Pregnancy (Hoboken, N.J.)·2026

Treatment patterns and costs among hospital births with abnormal postpartum uterine bleeding and postpartum hemorrhage in the United States (2016-2022).

Pregnancy (Hoboken, N.J.)·2026

Related Experiment Videos

Parity as prognostic factor for malignant mixed müllerian tumours

Related Concept Videos

Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1/ENGOT-ov25 trial.

An uncommon case of POLE mutated uterine carcinosarcoma - complemented by a review of literature.

ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease.

Combined chemotherapy and pembrolizumab salvages multi-chemotherapy agent and avelumab resistant choriocarcinoma: A case report.

Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial.

Continuous versus intermittent extended adjuvant letrozole for breast cancer: final results of randomized phase III SOLE (Study of Letrozole Extension) and SOLE Estrogen Substudy.

Efficacy and safety of upadacitinib in adults and adolescents for treatment of non-segmental vitiligo (Viti-Up): results of two phase 3 randomised controlled studies.

Belzutifan plus lenvatinib versus cabozantinib in patients with previously treated advanced renal cell carcinoma (LITESPARK-011): an open-label, randomised, controlled, phase 3 trial.

Switch to once-weekly, single-tablet islatravir-lenacapavir from daily standard of care for HIV-1 (ISLEND-2): a multicentre, randomised, open-label, active-controlled, phase 3 non-inferiority trial.

[177Lu]Lu-PSMA-617 in patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate cancer (PSMAddition): a phase 3 randomised, controlled trial.

Mixed Reality-Based Versus Nurse Practitioner-Delivered Wound Care Education in the Emergency Department: A Prospective Randomized Study.

Early Hospital Practices Were Associated With Exclusive Breastfeeding Among Late Preterm and Early Term Infants.

Society for Maternal-Fetal Medicine Position Statement: Maternal mortality review committees.

Paired versus alternate breastfeeding: Does hindmilk become foremilk?

Abortion-related training in maternal-fetal medicine fellowship: A national survey of program directors and fellows.

Treatment patterns and costs among hospital births with abnormal postpartum uterine bleeding and postpartum hemorrhage in the United States (2016-2022).

Related Experiment Videos

Parity as prognostic factor for malignant mixed müllerian tumours

Related Concept Videos

Related Articles